

14 Sep 2020 |

Infographic: Cancer Deal-Making In 2020

by **Joseph Haas**

Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 23 with upfront value of at least \$100m.

2020 has been a hectic deal-making year for the biopharmaceutical industry, with the most significant deals – [*Gilead Sciences, Inc./Immunomedics, Inc.*](#) and [*Merck & Co., Inc./Seattle Genetics, Inc.*](#) – occurring in recent days, despite the ongoing COVID-19 pandemic. Deal-making in cancer has been particularly voluminous, continuing the trend of recent years. In this infographic, we mine information from *Scrip* coverage from the and the Biomedtracker database to provide a snapshot of the year's cancer deal-making as of mid-September – highlighting the most significant acquisitions and alliances, gathering in one place the highest-value transactions, and also depicting which companies were most active and what development stages and therapeutic modalities saw the greatest activity.

[Click here to explore this interactive content online](#) ✨